Rovida Investment Management Ltd Has $16.15 Million Stock Holdings in ASP Isotopes Inc. $ASPI

Rovida Investment Management Ltd lifted its holdings in shares of ASP Isotopes Inc. (NASDAQ:ASPI) by 528.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,200,000 shares of the company’s stock after purchasing an additional 1,850,000 shares during the quarter. ASP Isotopes accounts for 3.0% of Rovida Investment Management Ltd’s holdings, making the stock its 8th largest position. Rovida Investment Management Ltd’s holdings in ASP Isotopes were worth $16,148,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. SBI Securities Co. Ltd. increased its holdings in ASP Isotopes by 84.8% in the 1st quarter. SBI Securities Co. Ltd. now owns 9,370 shares of the company’s stock valued at $44,000 after buying an additional 4,299 shares during the period. Bosun Asset Management LLC bought a new stake in ASP Isotopes during the first quarter worth $103,000. Perennial Advisors LLC acquired a new stake in shares of ASP Isotopes in the 2nd quarter valued at $110,000. SVB Wealth LLC raised its holdings in shares of ASP Isotopes by 132.2% during the 1st quarter. SVB Wealth LLC now owns 25,000 shares of the company’s stock worth $117,000 after buying an additional 14,235 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of ASP Isotopes by 9.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,613 shares of the company’s stock worth $148,000 after buying an additional 2,709 shares during the last quarter. 16.80% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Duncan Moore sold 75,000 shares of the firm’s stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $9.28, for a total transaction of $696,000.00. Following the completion of the sale, the director owned 994,553 shares of the company’s stock, valued at $9,229,451.84. This trade represents a 7.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Todd Wider sold 74,108 shares of the firm’s stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $8.76, for a total transaction of $649,186.08. Following the sale, the director directly owned 710,230 shares of the company’s stock, valued at approximately $6,221,614.80. This trade represents a 9.45% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 406,199 shares of company stock worth $3,718,977 over the last three months. Insiders own 21.40% of the company’s stock.

ASP Isotopes Stock Down 2.1%

Shares of NASDAQ:ASPI opened at $8.73 on Wednesday. The firm has a market cap of $815.47 million, a P/E ratio of -6.87 and a beta of 3.28. ASP Isotopes Inc. has a 12-month low of $3.65 and a 12-month high of $14.49. The business has a fifty day simple moving average of $9.65 and a 200 day simple moving average of $8.71. The company has a quick ratio of 14.56, a current ratio of 14.72 and a debt-to-equity ratio of 3.53.

ASP Isotopes (NASDAQ:ASPI) last released its quarterly earnings results on Thursday, August 14th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.92). ASP Isotopes had a negative return on equity of 239.22% and a negative net margin of 2,181.62%.The firm had revenue of $1.20 million for the quarter, compared to the consensus estimate of $1.60 million. Analysts predict that ASP Isotopes Inc. will post -0.24 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have issued reports on ASPI. Canaccord Genuity Group reiterated a “buy” rating and issued a $11.00 target price on shares of ASP Isotopes in a research report on Wednesday, September 17th. Weiss Ratings restated a “sell (e+)” rating on shares of ASP Isotopes in a research note on Thursday, October 30th. Finally, Loop Capital set a $15.00 price objective on shares of ASP Isotopes in a research report on Monday, October 27th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $13.00.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.